ObjectiveTo explore the clinical effect of enhanced external counterpulsation (EECP) assisted in treating patients with stable angina pectoris of coronary heart disease and its influence on the levels of serum inflammatory factors. MethodA total of 102 patients with stable angina pectoris of coronary heart disease admitted to our hospital from March 2019 to March 2020 were selected as the research objects, and they were divided into routine group and research group by the random number method, with 51 cases in each group. Patients in the routine group were given conventional treatment, based on which patients in the study group were received EECP for assisted treatment, for a treatment course of 6 weeks. The clinical efficacy was compared between the two groups. The onset of angina pectoris (frequency and duration), total myocardial ischemic burden, vascular endothelial function and serum inflammatory factors levels before and after treatment were compared between the two groups. The occurrence of major adverse cardiac events (MACE) after 6 months of treatment was compared between the two groups. ResultsAfter 6 weeks of treatment, the total effective rate of treatment in the research group (96.1%) was significantly higher than that in the routine group (78.4%), and the difference was statistically significant (P＜0.05). After 6 weeks of treatment, the frequency and duration of angina pectoris, and the total myocardial ischemia burden significantly decreased (shortened) in the two groups; compared to the routine group, the research group yielded superior indicators mentioned above, and the differences were statistically significant (P＜0.05). Before treatment, there were no statistically significant differences in endothelium-dependent flow-mediated dilation (FMD), endothelial-independent nitroglycerin-induced dilation (NMD), and the change rate of peak flow velocity (ΔVpeak) between the two groups (P＞0.05). After 6 weeks of treatment, the FMD and ΔVpeak significantly increased, whereas the levels of the research group were significantly higher than those of the routine group (P＜0.05). There was no statistically significant difference in NMD between the two groups (P＞0.05). Before treatment, there were no statistically significant differences in the serum complement C1q, complement C1q/tumor necrosis factor related protein 1 (CTRP1) levels between the two groups (P>0.05). After 6 weeks of treatment, the levels mentioned above significantly decreased in both groups, and the levels of the research group were significantly lower than those of the routine group, with statistically significant differences (P＜0.05). The incidence of MACE in the research group (3.9%) was significantly lower than that in the routine group (17.7%) within 6 months after treatment, and the difference was statistically significant (P＜0.05). ConclusionOn the basis of conventional treatment, EECP assisted to the treatment can significantly improve the clinical efficacy of patients with stable angina pectoris of coronary heart disease, effectively relieve angina pectoris frequency, improve myocardial ischemia and vascular endothelial function, relieve inflammatory responses, and decrease the incidence of MACE.

无